Clinical Trial Update: Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports the termination of a Phase 2 pharmacokinetic and efficacy study of Nordihydroguaiaretic acid (NDGA) in non-metastatic rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Nordihydroguaiaretic acid (NDGA) (Nordihydroguaiaretic acid)

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-04-09